Raiffeisen bank takes 10% stake in Austrian lung-diagnostics startup Lumetry
What's the deal? Raiffeisenlandesbank Niederösterreich-WienDealroom has a profile for this one. Try Dealroom → has acquired a 10% stake in Lumetry DiagnosticsDealroom has a profile for this one. Try Dealroom →, a Graz-based medical-technology startup. The deal value was not disclosed.
What does Lumetry do? Founded in 2022, the company researches lung diagnostics and monitoring, and develops and produces medical devices. Its backers already include Carbomed Medical Solutions and RLB Stmk TATEN, among others.
What's the endgame? Lumetry will use the capital to bring a CE-marked breath-analysis device for patients with chronic obstructive pulmonary disease (COPD) to market. The product targets a large and growing group of chronic-respiratory patients.
Why now? The investment follows a run of corporate activity at Lumetry, including several capital changes and new shareholders registered through 2026. Austrian banks have increasingly backed domestic medtech and life-sciences ventures as they look for stakes beyond traditional lending.
The signal: A regional bank taking equity in an early-stage medtech firm underlines how Austrian financial institutions are moving closer to the startup scene — betting that commercialising a certified medical device can turn research into revenue.
Read more: brutkasten.com
Image credit: NavyMedicine
